NCT Number: NCT06303713
Phase: PHASE1
Trial Summary: The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether t – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
LuCarbo – a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives